Go Back
NEUROCRINE BIOSCIENCES INC reports $76.6 million Q1 profit
By USInMinutes - May 03, 2023, 12:05 PM ET
Last Updated - Jul 18, 2023, 03:42 PM EDT
The company generated $420.40 million in quarterly revenue
NEUROCRINE BIOSCIENCES INC [NBIX] has reported fiscal Q1 profit of $76.60 million.
On a per-share basis, the DE based company said its diluted earnings are $0.79.
The Biological Products, Except Diagnostic Substances firm posted revenue of $420.40 million in this period.
Also Read:
- Neurocrine Biosciences to Present at the Bank of America Securities 2023 Healthcare Conference
- Neurocrine Biosciences to Present at the Bank of America Securities 2023 Healthcare Conference
- Neurocrine Biosciences Supports the Mental Health Community During Tardive Dyskinesia Awareness Week
- Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2023 Financial Results
- Neurocrine Biosciences Announces Results from the Real-World RE-KINECT™ Study Published in the Journal of Patient-Reported Outcomes Demonstrating the Effects of Possible Tardive Dyskinesia (TD) on Patient Health and Social Functioning
NewsInMinutes is an offering of 10kInfo, Inc., bringing you news on the latest regulatory filings. You may subscribe to news alerts here.
Sponsored
Sponsored
Read More from Investing
Popular News
Latest News
